[Protocol for the correct evaluation of CA 125 in pelvic tumescence]

. 1990 Oct-Dec;34(4 Suppl):75-8.

[Article in Italian]

Affiliations

[Article in Italian]

P Bonelli et al. J Nucl Med Allied Sci. 1990 Oct-Dec.

. 1990 Oct-Dec;34(4 Suppl):75-8.

No abstract available

Similar articles

[Experiences with the cancer marker CA 125 in gynecologic diseases].
Pilgrim G, von Broen B, Johannsmeyer KD. Pilgrim G, et al. Z Gesamte Inn Med. 1989 Apr 15;44(8):251-4. Z Gesamte Inn Med. 1989. PMID: 2741520 German.
Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
Torre GC, Barbetti V, Lanfranco E, Robutti M, Foglia M, Corongiu F, Vigliercio GP. Torre GC, et al. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):59-62. J Nucl Med Allied Sci. 1990. PMID: 2092151 No abstract available.
[Clinical evaluation of a cancer antigen CA 125 associated with ovarian cancer. (IV) Serum CA 125 levels through normal menstrual cycle and in benign diseases].
Suzuki M, Sekiguchi I, Ohwada M, Tamada T, Sakurabayashi I, Kawai T. Suzuki M, et al. Rinsho Byori. 1985 Mar;33(3):285-8. Rinsho Byori. 1985. PMID: 3859676 Japanese. No abstract available.
Clinical use of gynaecologic tumour markers.
Halila H, Alfthan H, Stenman UH. Halila H, et al. Ann Chir Gynaecol. 1989;78(1):65-70. Ann Chir Gynaecol. 1989. PMID: 2547331 Review.
[CA-125: a serum tumor marker in ovarian cancer].
Cohen AD, Piura B, Cohen Y. Cohen AD, et al. Harefuah. 1994 Feb 1;126(3):154-9. Harefuah. 1994. PMID: 8168751 Review. Hebrew. No abstract available.